Assessment and treatment of cardiac iron overload in thalassemia

A Aessopos1, D Farmakis, A Andreopoulos

  • 1First Department of Internal Medicine, University of Athens Medical School, Laiko Hospital, Athens, Greece. aaisopos@cc.uoa.gr

Hemoglobin
|December 17, 2009
PubMed

Insights

Cardiac disease is the leading cause of death in thalassemia major, with iron overload contributing to heart failure. Cardiac magnetic resonance (CMR) is the best method to assess heart iron, guiding tailored chelation therapy.

Area of Science:

  • Cardiology
  • Hematology
  • Medical Imaging

Background:

  • Thalassemia major is a severe inherited blood disorder.
  • Iron overload is a common complication of thalassemia major due to frequent blood transfusions.
  • Iron overload leads to multi-organ damage, particularly affecting the heart and causing heart failure.

Purpose of the Study:

  • To highlight the significance of cardiac iron overload in thalassemia major.
  • To emphasize the role of Cardiac Magnetic Resonance (CMR) in assessing cardiac iron.
  • To underscore the need for individualized chelation therapy based on iron load.

Main Methods:

  • Review of current literature on thalassemia major, iron overload, and cardiac complications.
  • Discussion of diagnostic methods for cardiac iron, focusing on CMR.
  • Analysis of treatment strategies for iron overload, including chelation therapy.

Main Results:

  • Cardiac disease is the primary cause of mortality in thalassemia major.
  • Cardiac iron accumulation is a major determinant of heart failure in these patients.
  • CMR is the gold standard for quantifying cardiac iron load.
  • Effective chelation therapy is crucial for preventing and managing cardiac complications.

Conclusions:

  • Cardiac iron overload is a critical factor in the morbidity and mortality of thalassemia major.
  • Regular monitoring of cardiac iron using CMR is essential for risk stratification.
  • Personalized and intensified chelation therapy, guided by CMR findings, can improve cardiac outcomes.

Related Concept Videos

Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Myocarditis IV: Nursing Management01:22

Myocarditis IV: Nursing Management

Myocarditis is an inflammatory condition of the myocardium requiring meticulous nursing management for optimal patient outcomes. Effective management begins with a thorough assessment of the patient's medical history, paying close attention to past infections, autoimmune disorders, travel history, and exposure to toxins or drugs. Recent viral infections and systemic diseases are particularly relevant due to their potential role in triggering myocarditis.Physical Examination and MonitoringThe...
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Cardiomyopathy VI: Nursing Management01:29

Cardiomyopathy VI: Nursing Management

Assessment: Nursing management of patients with cardiomyopathy begins with a thorough assessment of the patient's history, including a family history of cardiomyopathy or sudden cardiac death, personal history of heart disease, hypertension, diabetes, and any alcohol consumption or drug use.During the physical examination, assess vital signs, look for signs of heart failure (such as edema, jugular venous distention, and cyanosis), auscultate for abnormal heart sounds (like murmurs and gallops),...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...